Ilyang Pharmaceutical Co. says it will carry out a Phase III clinical trial of radotinib, a new leukemia medicine.
The drug is believed to be 30 times more effective than Gleevec, a popular anti-leukemia medicine.
If successful, it is expected to change the landscape of the leukemia drug market dominated by multinational drug firms.
The drug showed differing levels of efficacy dependi...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.